ArticleScientific reports2025
HIV case management using agent-based modeling approach subject to antiretroviral therapy and lifestyle treatment plan.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study presents a spatially explicit stochastic agent-based model (ABM) to simulate the complex non-linear interactions between T-cells, HIV virions, and therapeutic agents. The model framework operates on a two-dimensional grid, explicitly modeling biological entities as discrete agents to investigate the effects of antiretroviral drug therapy and specific lifestyle interventions. To benchmark model behavior, three distinct clinical stages of HIV infection were simulated under four comparative intervention scenarios. Quantification across 100 independent stochastic replicates per scenario demonstrated robust findings. The key result is that while antiretroviral drug therapy is essential for immediate viral suppression, the combination of drug therapy and lifestyle factors consistently produces a synergistic effect that leads to favorable long-term T-cell outcomes across all clinical stages simulated. Sensitivity analysis employed to assess the model's robustness identified the rate of wild-type virus production as the single most critical biological factor for viral control and clarified that the observed synergy stems mechanistically from lifestyle factors that boost T-cell proliferation, thereby improving immune recovery and promoting the clearance of infected T-cells. The comprehensive analysis in this study presents that a holistic management approach, integrating pharmacological and lifestyle interventions, provides a crucial synergistic effect that promotes sustained immune health. The model presented in this study serves as an exploratory framework for investigating optimal and personalized HIV treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.